Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody HT31-1 enters human trials for ARDS

NCT ID NCT07449572

Recruiting now Disease control Sponsor: HTIC, Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new antibody called HT31-1 in 24 healthy volunteers to see if it is safe and how the body processes it. The antibody targets a protein linked to inflammation in acute respiratory distress syndrome (ARDS), a severe lung condition often caused by infections. If successful, this study will guide future testing in ARDS patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HT31-1 (a lab-made antibody targeting citrullinated histone H3)
What this could lead to
If safe and effective, this could lead to a new treatment for acute respiratory distress syndrome (ARDS) caused by infections.
What could go wrong
This is a very early Phase 1 trial in only 24 healthy people, so it may not work in patients or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME)

Contacts and locations

Locations

  • Virginia Commonwealth University (VCU Health)

    NOT_YET_RECRUITING

    Richmond, Virginia, 23298, United States

  • Virginia Commonwealth University (VCU Health)

    RECRUITING

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.